{"filing":{"accession_number":"0001193125-26-276693","cik":"0001783328","ticker":"TCRX","company_name":"TScan Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d103234d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/d103234d8k.htm"},"events":[{"id":12571,"run_id":11150,"accession_number":"0001193125-26-276693","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"TScan announced positive initial data from Cohort C of its Phase 1 ALLOHA™ study evaluating TSC-101, including manufacturing success rates, patient enrollment, chimerism outcomes, and safety results, with confirmation that the company remains on track to initiate a Phase 3 pivotal study. This represents a material clinical development milestone for the company's lead product candidate.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9458,"accession_number":"0001193125-26-276693","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TScan announced positive initial data from Cohort C of its Phase 1 ALLOHA™ study evaluating TSC-101, including chimerism outcomes and safety results, along with confirmation that the company remains on track to initiate a Phase 3 pivotal study. This is a material clinical development milestone for a lead product candidate, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on clinical trial progress and product development advancement, making it an operational/strategic milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:11:12.049919+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9459,"accession_number":"0001193125-26-276693","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"TScan disclosed positive clinical trial data from Cohort C of its Phase 1 ALLOHA study evaluating TSC-101, including manufacturing success rates, patient enrollment, chimerism outcomes, and safety results. This represents a material operational/clinical milestone for a clinical-stage biotech company—the data supports advancement to Phase 3 trials and demonstrates progress on the lead product candidate. While not a formal earnings release, earnings announcement, or other specifically-named event type, this clinical data disclosure is clearly material to investors assessing the company's pipeline progress and product viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:11:12.049919+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9458,"accession_number":"0001193125-26-276693","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TScan announced positive initial data from Cohort C of its Phase 1 ALLOHA™ study evaluating TSC-101, including chimerism outcomes and safety results, along with confirmation that the company remains on track to initiate a Phase 3 pivotal study. This is a material clinical development milestone for a lead product candidate, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on clinical trial progress and product development advancement, making it an operational/strategic milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:11:12.049919+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-06-22"},{"id":9459,"accession_number":"0001193125-26-276693","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"TScan disclosed positive clinical trial data from Cohort C of its Phase 1 ALLOHA study evaluating TSC-101, including manufacturing success rates, patient enrollment, chimerism outcomes, and safety results. This represents a material operational/clinical milestone for a clinical-stage biotech company—the data supports advancement to Phase 3 trials and demonstrates progress on the lead product candidate. While not a formal earnings release, earnings announcement, or other specifically-named event type, this clinical data disclosure is clearly material to investors assessing the company's pipeline progress and product viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:11:12.049919+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-06-22"}]}